Healthy Approach
    Category: Companies & People By : Aastha Maheshwari and Anushka Dhoot Read : 701 Date : Friday, November 10, 2017 - 09:30:46

    In Indonesia, French pharmaceutical giant Sanofi is a leading consumer healthcare company, with a focus on vaccines and treatments for diabetes, Thrombosis, hypertension and rare diseases. “Within the diversity of our portfolio we want to focus on how we can make an impact, and which are the treatments where we can make a big change,” says Sanofi Indonesia President Director Benoit Martineau, 37, a Frenchman who took charge in 2014. Sanofi claims to be largest multinational in Indonesia, as ranked by sales, with were Rp 1.4 trillion last year. It operates here under the name PT Aventis Pharma.

    Benoit arrived just as Indonesia was launching its most ambitious healthcare plan, the National Health Insurance scheme (BPJS), which aims to provide universal healthcare to all Indonesians. The BPJS’s implementation has changed the landscape of the Indonesian healthcare market, impacting many public and private companies.

    To stay competitive under the era of BPJS, Sanofi has innovated and upgraded itself. “For instance, for oncology, more than 90% patients are public patients. So, you must be under the government’s health scheme with your oncology products, as the private sector segment will eventually become expensive and really small,” he says. Benoit says he is focusing on three main segments to maintain growth, which is currently around 7% a year.

    1. Prescription products, which make up half of all sales, mostly for Thrombosis and diabetes treatments.
    2. Vaccines, which are 25% of sales, mostly for pediatric vaccine and Thrombosis vaccines.
    3. Consumer healthcare, which are the final 25% of sales, and which is showing significant growth.

    Sanofi uses Indonesia as an important manufacturing and export base, producing locally about half of all the products it sells here (and imports the rest). The company also exports about half of its local production to the Asia-Pacific market, including Australia and New Zealand. Its partner here is local pharmaceutical firm PT Usaha Minidin Raya.

    The company has recently launched a new tagline, “Empowering Life,” signifying its commitment to be a healthcare leader. Apart from its flagship dengue treatments, vaccinations, diabetes treatments, the company also provides a range of non-prescription medicines, such as for colds and back pain, as well as vitamins and other supplements. Despite a presence in Indonesia that stretches back 60 years, Benoit says there is plenty of opportunity in the country, especially to improve its distribution, now already spread to 45 cities. “The main question we are dealing with today is reach and penetration. There are just 100,000 doctors in Indonesia, and thus coping with infrastructure, to treat maximum number of people, has become a big necessity,” Benoit says.

    Read full version of the article